

CSU IBC Meeting – APPROVED MINUTES

Meeting title	CSU IBC Meeting August 2026
Date	August 12, 2026
Convened at	8:31am
Location	TMI Rm 222
Open or closed meeting (If closed, why?)	The meeting was closed briefly to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
Review of prior meeting minutes	June 17, 2026 IBC meeting minutes approved as written
Adjournment	9:57am
Recorded by	R. Moritz

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
☒ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☒ Donald Bade, Unaffiliated	
☒ Angela Bosco-Lauth, Chair	
☒ Joshua Chan, Synthetic Biology	
☒ Chaoping Chen, Retrovirology	
☒ Jason Cummings, Lab Representative	
☒ Marc Nishimura, Plant Expert	
☒ Brendan Podell, Mycobacteria specialist	
☐ Ann Powers, Virology	
☒ Robyn Roberts, Assoc Chair/Plant expert	
☒ Joanie Ryan, Assistant Biosafety Director	☒ Rebecca Moritz, Biosafety Office Director*
☒ Carrie Satterwhite, Unaffiliated	☒ Peter O'Brien, Alternate Unaffiliated*
☐ Tony Schountz, Virology	☐ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; <u>11</u> in attendance	*non-voting at this meeting
Non-Voting Members:	
☒ Joni Van Sickle, Occupational Health Coord	
☐	
ORCC Staff (non-voting):	
☐ Michelle Ramey, Assistant Compliance Coord.	☒ Sonia Aleman Rivera, Assistant Biosafety Officer
☐ Nicole Marlenee, Biosecurity Specialist	☒ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Recognition of Outgoing Chair, Chaoping Chen

Chaoping was thanked for her 12 years of service as IBC Chair. She was presented with gifts and cards signed by IBC members.

2. New member introductions

The new IBC members were introduced. The rest of the committee introduced themselves and welcomed the new members.

3. Review of June 17, 2026, IBC meeting minutes (there was no meeting in July)

The meeting minutes from June 17, 2026 were reviewed and approved as written.

4. Agent/Project Review

a. PI name/Lab	McGrath Lab – Assigned Reviewers: Jessica, Don, Joanie
Project Number and Title	26-033B: Assessing Safety of Bioengineered EcN 1917 as a Bacterial Living Logic Cancer Therapy
Project Overview	This project will evaluate the safety and efficacy of a systemic bacterial cancer therapy targeting canine gliomas.
Planned Modifications	In vivo administration of modified bacteria
Agents used	Escherichia coli Nissle 1917 (EcN 1917)
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL1/ABSL-1
Discussion	- Please confirm whether the bacteria is shed. - If the bacteria is not shed/excreted, then standard cleaning procedures will be sufficient. - Please associate the genetically modified E. coli strain with to the project. - Please add the specific rooms as housing facility locations and specify which procedures will occur in which areas.
Verification of training	All training is up to date.
Verification of facilities	The Lab is due for its Biosafety Outreach visit.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
b. PI name/Lab	Schenkel Lab – Assigned Reviewers: Chaoping, Joshua, Joanie
Project Number and Title	26-036B: Analyses of human lung immune responses to acute and chronic infections
Project Overview	We are collecting blood and tissue samples for single cell RNA sequencing and analysis of the immune responses to vaccines, long term inflammation, etc. We are also exploring the functions of SARS-CoV-2 ORF8 protein in human cells.
Planned Modifications	CaLu3 cells will be transduced with GFP+ Luciferase reporter gene
Agents used	lentivirus vector
NIH Guidelines Section	III-D-3

Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	1. What is the purpose of using lung tissue from patients previously diagnosed with non-tuberculosis Mycobacteria infections? 2. Where are the NHP samples from? 3. Please clarify how the human lung tissue is inactivated for NTMs.
Verification of training	Shipping training required for personnel.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
c. PI name/Lab	Myers Lab – Assigned Reviewers: Chaoping, Joshua, Joanie
Project Number and Title	26-039B: Celltype-specific retrograde tracing in the nervous system
Project Overview	Glycoprotein-deleted rabies virus (RVΔG) is a specially modified virus used to map how neurons connect in the brain. It's not a live virus that causes rabies, it's an engineered tool for studying brain circuits. For these studies, we will administer a combination of viruses to examine the brain-wide inputs to a population of hypothalamic dopamine neurons.
Planned Modifications	In vivo administration of modified virus
Agents used	Glycoprotein-deleted rabies virus (RVΔG)
NIH Guidelines Section	III-D-1; III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	The Pathogen Registration Form for the agent is missing, cannot properly assess the risks of the work.
Verification of training	Training up to date for all Lab members.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to table the project until the Pathogen Registration Form is submitted.
Vote	The motion was unanimously approved.

5. Amendments requiring full IBC review

d. PI name/Lab	Telling Lab – Assigned Reviewers: Tony, Angela, Joanie
Project Number and Title	11-062B: Prion disease research
Project Overview	The purpose of these studies is to create new experimental animal and cell culture models in which prion pathogenesis can be studied. In one approach, transgenic mice are produced that express foreign PrP genes. Our cell culture approaches involve the expression of genetically altered forms of PrP in cultured cells and the study of PrP processing and trafficking. Finally, we employ a technique referred to as protein misfiling cyclic

	amplification (PMCA) in which prion replication can be studied under cell free conditions.
Planned Modifications	Manipulation of PrP expression constructs to increase or decrease expression
Agents used	Prions
NIH Guidelines Section	III-D-4, III-E-1
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL-2
Amendment request	Multiple updates, reviewed as if new
Discussion	1. Can prions (CJD) be transmitted via bite? If yes, either bite-resistant gloves or tongs should be used to handle mice that are not anesthetized. 2. Under "in vivo uses" the face shield and N95 each say "N". Based on the information in the body of the text, this should be changed to Y. 3. Specify which assays/procedures require the use of N95 and whether LAR needs to use them. 4. Please confirm that all individuals using N95s are enrolled in the Occ Health respirator program.
Verification of training	Training up to date for all Lab members.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project amendment with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
e. PI name/Lab	Woerman Lab – Assigned Reviewers: Tony, Angela, Joanie
Project Number and Title	23-039B: Investigating prion strain biology
Project Overview	In healthy individuals, the proteins tau and alpha-synuclein misfold into prions that then spread throughout the brain giving rise to neurodegenerative diseases. This laboratory investigates the mechanisms by which this process occurs, how the proteins misfold into different shapes (or strains) to cause unique neurodegenerative disorders, the pathogenesis of each prion strain, and tools for diagnosing and treating patients with these disorders. To accomplish this, we use a variety of tools, including immortalized cell lines expressing fusion proteins where our protein of interest is labelled with a fluorescent protein, primary neurons, and transgenic mice.
Planned Modifications	Using CRISPR prime editing for editing the gene sequence
Agents used	prions
NIH Guidelines Section	III-D-2, III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2+/ABSL-2+
Amendment request	Multiple updates, reviewed as new
Discussion	It is unclear if the brain homogenate is derived from human, mouse or some other species. Please clarify.

Verification of training	Training up to date for all Lab members.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project amendment with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
f. PI name/Lab	Schountz Lab – Assigned Reviewers: Angela, Chaoping, Joanie
Project Number and Title	20-008B: Experimental infection of Jamaican fruit bats with SARS-CoV-2 coronavirus
Project Overview	This project will determine the susceptibility of Jamaican fruit bats (<i>Artibeus jamaicensis</i> ; in vivo) and its cells (in vitro) to SARS-CoV-2.
Planned Modification	virus was generated by reverse genetics
Agents used	• SARS-CoV-2
NIH Guidelines Section	III-D-1
Proposed containment conditions (BSL, ABSL, etc.)	ABSL-3/BSL-3
Amendment request	Adding agent: OC43-CoV
Discussion	1. The amendment mentions submitting tissues to determine viral antigen detection and histopathology. Where will samples be submitted? Will they be inactivated? 2. Please provide the SOP for inactivation and removal from containment 3. Clarify that intention of infection with OC43-CoV is to see if it alters the course of disease, not to enhance it. 4. It is recommended this project be deferred to the IRE out of an abundance of caution.
Verification of training	One individual needs to update NIH Guidelines and BBP training
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project amendment with clarifications described above (see Discussion) and IRE review.
Vote	The motion was unanimously approved.

6. New Business

a. U.S. Government Policy for Stopping High-Risk Life Sciences Research

The IBC was informed of the new dangerous gain of function policy that was released by the federal government on July 20th. This policy will replace all previous DURC/PEPP policies and must be fully implemented by institutions by January 16, 2027. We are working on determining what implementation will look like for CSU and will share updates with the committee as they become available.

7. Unfinished Business

a. NIH Initiative to Modernize and Strengthen Biosafety Oversight

(<https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/>)

No updates at this time

8. Closed Session

Items to discuss

9. Reports

a. Coordinator's Report	1. Our annual report/roster update was approved by NIH OSP on 8/6/26. 2. Member survey for Fall semester meeting schedule 3. Next IBC meeting: Wednesday, September 9, 2026
b. Biosafety Office Report	1. Inspections update: none 2. Incident Reports: no incidents involving rDNA were reported.

10. Public Comment

None

11. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	a. Peebles Lab Project: <u>Generation of a biosensor to enhance olfaction v2</u> (26-023B); BSL1. NIH Guidelines category non-exempt rDNA: III-D-2 b. Harris Lab Project: <u>Modeling CHIP-Associated Myeloid Rewiring in DLBCL</u> (26-025B); BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: III-D-3 and III-D-4. Project: <u>Dissecting NRAS-Mediated Leukemic Stem Cell Persistence to Enable Durable AML Therapy</u> (26-026B); BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: NA
---	--